An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Foscarbidopa/Foslevodopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors AbbVie
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 26 May 2020 Results from this study, were presented at the 6th Congress of the European Academy of Neurology.
- 01 May 2020 Final results presented at the 72nd Annual Meeting of the American Academy of Neurology